FGF9

FGF9 Full Name

fibroblast growth factor 9 (glia-activating factor)

FGF9 Introduction

FGF9 (Fibroblast Growth Factor 9) encodes a 208-amino acid heparin-binding growth factor that belongs to the FGF9 subfamily, which also includes FGF16 and FGF20 based on structural homology and functional similarity. Initially identified as a glia-activating factor (GAF) from glioma cell culture supernatant, the protein exists as both monomeric and homodimeric forms, with the monomer-dimer equilibrium regulated by specific amino acid residues that control its affinity for heparin sulfate proteoglycans. FGF9 exhibits preferential binding to specific fibroblast growth factor receptors, primarily FGFR2 and FGFR3, and its affinity for these receptors is modulated by heparan sulfate glycosaminoglycans that function as coreceptors. The gene is located on chromosome 13q12.11, contains three exons, and is positioned in a head-to-head orientation with the EFHA1 gene.

Figure 1. Strcuture of FGF9.

Organ Development and Morphogenetic Functions
FGF9 plays indispensable roles in the development of multiple organ systems, particularly the lungs, limbs, and kidneys. During lung development, mesothelium-produced FGF9 is principally responsible for mesenchymal growth, while epithelium-produced FGF9 signals through epithelial FGFR3 to directly promote distal epithelial fate specification and inhibit epithelial differentiation. This FGF9-FGFR3 signaling functionally opposes FGF10-FGFR2b signaling, with FGFR3 preferentially using downstream phosphoinositide 3-kinase (PI3K) pathways while FGFR2b relies on mitogen-activated protein kinase (MAPK) pathways. In limb development, FGF9 functions as one of the apical ectodermal ridge fibroblast growth factors (AER-FGFs) that work in a positive feedback loop with Sonic hedgehog (SHH) to control limb patterning and skeletal formation. FGF9 also acts redundantly with FGF20 as a niche signal required to maintain nephron progenitors in an undifferentiated state during kidney development.

Oncogenic Mechanisms in Human Cancers
FGF9 exhibits context-dependent roles in cancer biology, functioning as an oncogenic driver in several malignancies. In glioblastoma, FGF9/FGFR2 signaling is significantly elevated and drives mitochondrial biogenesis through the CREB-PGC-1α-TFAM axis, enhancing mitochondrial DNA content, mitochondrial mass, complex activity, membrane potential, and ATP production to meet the heightened metabolic demands of tumor cells. Serum FGF9 levels are markedly higher in glioblastoma patients compared to healthy controls, and FGFR2 mRNA and protein are elevated in tumor tissues. Somatic FGF9 mutations have been identified in colorectal and endometrial carcinomas, including frameshift, missense, and nonsense mutations, many of which are predicted to cause loss of function through impaired ligand-receptor interaction, reduced heparin affinity, or defective protein folding. Loss of heterozygosity at the FGF9 locus on 13q12.11 is frequently observed in these tumors, and FGF9 mutant tumors often show normal membranous β-catenin expression, suggesting that FGF9 plays a role in carcinogenesis through mechanisms distinct from canonical Wnt pathway activation.

Alternate Names for FGF9

FGF9; fibroblast growth factor 9 (glia-activating factor); fibroblast growth factor 9; FGF-9; HBGF-9; heparin-binding growth factor 9; GAF; SYNS3; HBFG-9; MGC119914; MGC119915;